13 November 2015

Dear [Name]

Your email of 26 October 2015

I refer to your request of 26 October 2015, which we have treated as a request under the Freedom of Information Act 2000. This has been passed to me to deal with. I confirm that while some of the information is held given our contracting arrangements it is not held in the form you have requested. I set out our responses to your questions in the table below. I note in passing that Genomics England Ltd was only created in April 2013. You should also note that Genomics England only became a separate accounting entity from the Department of Health on 1 April 2014 and therefore we only have 1 year’s accounts, which you are welcome to a copy of (they are accessible at Companies House).

| Approximate value of spending by Genomics England (and its subcontractors) on genomics infrastructure, surveillance, research, and clinical services (and the development thereof) since 2008 |
|---|---|
| **Question** | **Response** |
| 1. Investment in buildings and their maintenance | • We rent office space from QMUL on a short term basis at a peppercorn rent with a service charge of £116k pa indexed.  
• Wellcome Trust Sanger Institute (Sanger) has procured the construction of a new sequencing centre on its campus at Hinxton which was completed at the end of August. Sanger will make available the basement floor to us at a nil rent for us to sublet to Illumina (Cambridge) Ltd. We will pay a service charge, the bulk of which covers utilities. The lease is still under negotiation. |
| 2. Capital equipment and maintenance thereof (e.g. liquid handlers for library preparation, equipment for cluster generation (such as the Illumina cBot), sequencers, and computational infrastructure) | We have not spent any money on capital equipment or its maintenance. We have contracts with:  
• Illumina (Cambridge) Ltd to providing sequencing for the duration of the project. The payments under this contract are considered to be commercially sensitive (see below regarding the availability of the contract);  
• UK Biocentres to provide sample handling during the life of the project for a cost of around £1m;  
• NHS Blood and Transport to transport samples to UK Biocentre. We have a contract dated 4 March 2015 and running until 31 December 2017 under which we pay NHSBT £41,500 per annum;  
• Omicia Inc and Congenica Ltd to provide clinical interpretation services (the prices are considered to be commercially sensitive);  
• NHS England (who in turn has contracts with Genomic Medicine Centres to provide samples and data for the programme). No |
<table>
<thead>
<tr>
<th>3. Consumables related to sequencing</th>
<th>These are included in the sequencing costs under the contract with Illumina. The contract is available at <a href="https://www.whatdoolyknow.com/request/agreements_between_genomics_eng#outgoing-402446">https://www.whatdoolyknow.com/request/agreements_between_genomics_eng#outgoing-402446</a> but the costs are commercially sensitive.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Aggregated personnel costs (e.g. for bioinformatics, IT, wet laboratory, and management).</td>
<td>Including GEL staff, seconded staff and contractors the total was £3.5 million in the financial year to 31 March 2015.</td>
</tr>
<tr>
<td>5. R&amp;D, proof-of-concept, development, and strategic awards in genomics (e.g. awards to external partners, such as universities), should these figures not already be included in the aforementioned categories</td>
<td>We have been involved in a SBRI genomics competition which has awarded £2m to 8 companies at Phase 1 and a further £8m to 5 companies at Phase 2. We did not include either the funds received from DH or the payments to the SBRI competition winners in our accounts on the basis that we were merely acting as an agent for the DH in making the payments.</td>
</tr>
<tr>
<td>Please specify how much money, if any, Genomics England has received or is expected to receive/earn from outside the agency and, if applicable, include the source(s) of this income (e.g. as part of the 100,000 genome project, from industry, or charging for services).</td>
<td>In the year to 31 March 2015 we received £250k from pharmaceutical companies as a membership fee for our GENE Consortium. The GENE Consortium comprises 12 companies and runs until 30 June 2016.</td>
</tr>
<tr>
<td>Expenditure on IT in 14/15</td>
<td>We spent £136,000 on IT in the year to 31 March 2015. MRC has awarded a £24m grant in respect of the programme. However, the award holder is Queen Mary University of London. Under the terms of the award £6m was spent on IT in 14/15 and a further £18m is due to be spent in the current financial year. QMUL owns the assets procured under the grant.</td>
</tr>
</tbody>
</table>

If you have any queries about this letter, please contact me.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Grant Stapleton  
Senior Information Responsible Officer  
Genomics England

Email: [grant.stapleton@genomicsengland.co.uk](mailto:grant.stapleton@genomicsengland.co.uk)
If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner (ICO) for a decision. Generally, the ICO cannot make a decision unless you have exhausted the complaints procedure provided by the Department. The ICO can be contacted at:

The Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Kind regards

Yours sincerely

[REDACTED]

GENERAL COUNSEL